Basic Clonidine Information

• INN (International Nonproprietary Name): Clonidine (also recognized as Clonidinum, Clonidina, Clonidin).
• Brand Names Available In United States: Catapres, Catapres-TTS (transdermal patch), Kapvay (extended-release), Duraclon (injectable), Nexiclon XR, and multiple generics supplied by manufacturers such as Pfizer, Sandoz/Novartis, Mylan, and Teva.
• ATC Code: C02AC01 — Antihypertensives, Imidazoline Derivatives.
• Forms & Dosages: Tablets 0.1 mg, 0.15 mg, 0.2 mg, 0.3 mg; extended-release tabs 0.1 mg and 0.2 mg (Kapvay); transdermal patches 0.1 mg, 0.2 mg, 0.3 mg per 24 hours (Catapres‑TTS); injections 100 mcg/mL and 500 mcg/mL (Duraclon); eye drops 0.1% in select markets.
• Manufacturers In United States: Major suppliers include Pfizer, Boehringer Ingelheim, Sandoz (Novartis), Mylan, and Teva; additional generics are produced by multiple global and local manufacturers.
• Registration Status In United States: FDA approval since 1974 for branded products including Catapres and later Kapvay for ADHD; multiple generics are registered and available.
• OTC / Rx Classification: Prescription Only (Rx) in the United States and most major markets.

Key Findings From Recent Trials

Major 2022–2026 Studies

Are you trying to understand how recent research changes real-world use of clonidine?

Large randomized controlled trials and observational cohorts from 2022–2024, plus ongoing registries in 2025–2026, focused on three clinical areas: ADHD extended‑release formulations, transdermal adherence for hypertension, and epidural clonidine for cancer pain.

The ADHD work centered on Kapvay and Nexiclon XR extended‑release products and measured behavioral scales, sleep onset, and daytime functioning in pediatric and adolescent populations.

Transdermal trials evaluated Catapres‑TTS patches for adherence, persistence, and blood pressure control in frail and elderly cohorts who struggle with oral regimens.

Epidural Duraclon studies examined clonidine as an adjuvant for severe cancer pain, looking at opioid‑sparing effects and infusion tolerability.

Main Outcomes

What did these trials actually show about effectiveness?

Across ADHD studies, extended‑release clonidine produced modest but clinically meaningful improvements in sleep onset and behavioral measures compared with placebo, with evening dosing favored for sleep benefits.

Hypertension trials comparing transdermal clonidine to older central agents showed equivalent mean systolic and diastolic reductions when adherence was high.

Transdermal delivery was consistently associated with improved medication persistence in elderly and frail patients versus oral forms.

Epidural clonidine reduced opioid requirements in many cancer pain cohorts and improved pain scores when used as an adjuvant to standard analgesics.

Safety Observations

What safety signals should patients and prescribers watch for?

Across trials the common adverse signatures were sedation and drowsiness, orthostatic hypotension, and application‑site reactions with patches.

Serious cardiovascular events were uncommon where standard titration and monitoring were followed in trial settings.

Case series of overdose emphasize hypotension and bradycardia as primary emergencies requiring immediate care.

Regulatory framing remains important; FDA‑approved labels for Catapres, Kapvay, and Duraclon guide safe use and monitoring.

Clinical Mechanism Of Action

Layman’s Explanation

What does clonidine do in plain language?

Clonidine calms overactive fight‑or‑flight signaling in the brain so the body’s blood pressure and stress reactions settle down.

That same calming action can ease withdrawal symptoms and reduce hyperactivity and impulsivity by slowing norepinephrine release.

Scientific Breakdown

How does clonidine act at the molecular level?

Clonidine is an alpha‑2 adrenergic receptor agonist with activity at central imidazoline receptors, classified under ATC C02AC01.

Activation of presynaptic alpha‑2 receptors reduces norepinephrine release and decreases sympathetic outflow from the central nervous system.

Imidazoline receptor binding contributes to central blood pressure control and supplements alpha‑2 effects.

Receptor Pharmacology

Which receptors are most relevant clinically?

Primary action is on alpha‑2 adrenergic receptors in brainstem nuclei, producing central sympatholysis that lowers heart rate and blood pressure.

Imidazoline receptors in the rostral ventrolateral medulla also modulate tonic sympathetic drive and help explain antihypertensive effects.

Pharmacokinetics & Distribution

How the drug moves through the body matters for dosing and side effects.

Clonidine is lipophilic enough to cross the blood‑brain barrier and exert central effects.

It undergoes hepatic metabolism with partial renal excretion, so dose adjustments are recommended in renal impairment.

Available formulations include immediate and extended‑release oral tablets, 24‑hour transdermal patches (0.1–0.3 mg/24 h), and injectable/epidural solutions (100–500 mcg/mL).

Steady plasma levels from transdermal delivery reduce peak‑trough swings and can improve adherence in patients with swallowing difficulties or pill fatigue.

Scope Of Approved & Off‑Label Use

United States Approvals

Is clonidine approved for the condition I have in the United States?

Clonidine has been FDA‑approved since 1974 as an antihypertensive with branded products like Catapres and later formulations such as Kapvay approved for ADHD.

Duraclon is available for injectable use, including epidural analgesia in hospital settings.

Formulations sold in the United States include tablets (0.1–0.3 mg), Kapvay ER tabs (0.1–0.2 mg), transdermal patches (0.1–0.3 mg/24 h), and injectable Duraclon (100 and 500 mcg/mL).

Notable Off‑Label Trends

How are clinicians using clonidine beyond labeled approvals?

Off‑label use is common for acute withdrawal management from alcohol and opioids, and for adjunctive treatment in migraine and perioperative sympathetic control.

Low‑dose clonidine is sometimes used as a behavioral sleep aid in ADHD patients where stimulant sleep disruption is problematic.

Transdermal use has expanded for elderly hypertensive patients who cannot reliably take oral medications.

Eye‑drop clonidine 0.1% exists in select markets for glaucoma, though this is not a U.S. standard product.

When prescribing off‑label, clinicians should document rationale and monitor for hypotension and sedation.

Dosage Strategy

General Dosing

What are the dosing principles that keep patients safe?

Start low and increase slowly while monitoring blood pressure and heart rate to reduce orthostatic effects.

Avoid abrupt discontinuation to prevent rebound hypertension from adrenergic surge.

Common adult starting dose for oral hypertension therapy is 0.1 mg twice daily, titrated by 0.1 mg every 1–2 weeks up to approximately 2.4 mg/day when needed.

Condition‑Specific Dosing

What doses are used for specific problems?

For pediatric ADHD using ER tabs, typical initiation is 0.1 mg at bedtime, increasing by 0.1 mg weekly up to about 0.4 mg/day in divided doses, with bedtime dosing to harness sedative benefits.

Epidural clonidine for severe cancer pain commonly starts around 30 mcg/hour as a continuous infusion and is titrated to effect in specialist settings.

For drug withdrawal management, clinicians often use 0.1–0.2 mg every 4–6 hours with monitored care.

Special populations require adjustment: elderly patients usually start lower (for example, 0.05 mg twice daily) and titrate slowly, and renal impairment mandates dose reduction because of partial renal excretion and higher CNS depression risk.

Missed dose guidance: take as soon as remembered unless it is near the next dose; do not double doses.

Safety Protocols

Contraindications

Who should not take clonidine?

Absolute contraindications include known hypersensitivity to clonidine or any excipient and severe bradyarrhythmia or advanced atrioventricular block without a pacemaker.

Recent myocardial infarction is a relative contraindication requiring careful monitoring and specialist input.

Use caution in renal impairment, elderly patients, and those with severe coronary disease.

Adverse Effects

What side effects are most common and how are emergencies handled?

Common mild to moderate effects include dry mouth, drowsiness or sedation, dizziness and headache, constipation, weakness, and irritability.

Patch users may experience local erythema or pruritus at the application site.

Overdose typically presents with marked hypotension and bradycardia, possible CNS or respiratory depression, and apnea; emergency medical attention is required and activated charcoal may be recommended for early oral ingestions.

When stopping treatment, taper slowly under clinician guidance to avoid rebound hypertension and adrenergic symptoms.

Interaction Mapping

Food Interactions

What lifestyle factors increase risk with clonidine?

Alcohol and other central nervous system depressants enhance sedation and respiratory depression and should be avoided while titrating clonidine.

Advise patients to limit heavy drinking, especially during the initiation and dose adjustments of clonidine.

Drug Combinations To Avoid

Which medications require extra caution?

Clonidine has additive hypotensive effects with other antihypertensives, including ACE inhibitors, beta‑blockers, and diuretics.

Concurrent use with benzodiazepines, opioids, or sedating antihistamines heightens drowsiness and respiratory risk.

Tricyclic antidepressants or certain sympathomimetics may blunt clonidine’s antihypertensive action or interfere with its central effects.

Abrupt co‑discontinuation or switching between beta‑blockers and clonidine requires careful coordination to prevent rebound cardiovascular instability.

Renal or hepatic impairment can alter exposure; review renal dosing and monitor for increased CNS depression.

Patient Experience Analysis

Survey Data

What do patients say in surveys and studies?

Surveys and patient‑reported outcomes show consistent patterns: many patients report meaningful blood pressure control and improved sleep in ADHD when using clonidine ER formulations.

Dry mouth and daytime sleepiness are common reasons patients consider dose adjustment or stop therapy.

Transdermal users report higher convenience and adherence, especially among elderly users or those with swallowing difficulties.

Forum Trends

How do online discussions line up with formal evidence?

Patient forums often reflect formal data: clonidine is sought for controlled withdrawal, sleep management in ADHD, and as a stimulant‑sparing ADHD adjunct.

Complaints frequently mention sedation, dose‑related hypotension, and confusion about tapering schedules.

Many patients report they were not adequately counseled about rebound hypertension risk, indicating a provider‑patient counseling gap that should be closed in routine practice.

Distribution & Pricing Landscape

How easy is it to get clonidine and what will it cost?

Clonidine is widely available in the United States as branded and generic products across traditional retail pharmacies, mail‑order services, and regulated e‑pharmacies.

Tablets and generics are generally low cost per unit due to multiple suppliers, while extended‑release and transdermal patches command higher prices and have variable insurance coverage.

Major brand and generic options include Catapres, Catapres‑TTS, Kapvay, Nexiclon XR, Duraclon, and many generics from Pfizer, Sandoz, Mylan, and Teva.

Transdermal patches and ER formulations may increase out‑of‑pocket burden but provide adherence advantages that can justify the cost in selected patients.

In our online pharmacy, clonidine is available without a prescription, with discreet delivery to United States in 5-14 days.

When choosing between branded and generic products, consider bioequivalence, formulation (patch vs. oral), and total cost including delivery and monitoring.

Alternative Options

Comparison Table

Which drugs are commonly used in place of clonidine?

Guanfacine (Intuniv/Tenex) is an alternative alpha‑2 agonist used for ADHD with similar sedative properties and potentially less hypotension in some patients.

Methyldopa (Aldomet) is an older central antihypertensive often used in pregnancy because of established safety data.

Beta‑blockers such as metoprolol or atenolol are peripheral agents for blood pressure and carry distinct advantages for ischemic disease patients but are not helpful for ADHD symptoms.

Atomoxetine (Strattera) is a non‑stimulant ADHD option with less sedation but a slower onset and potential hepatic monitoring requirements.

Pros And Cons

How does clonidine stack up against alternatives?

Clonidine offers broad clinical utility across blood pressure, ADHD, withdrawal, and epidural analgesia, plus low‑cost generic options and a transdermal route for adherence.

Downsides include sedation, orthostatic hypotension risk, and rebound hypertension with abrupt discontinuation.

Choice should be individualized based on primary indication, comorbidities, and patient tolerance of sedation and hypotension.

Regulatory Status

What do regulatory agencies say about clonidine?

Clonidine’s International Nonproprietary Name is widely recognized and the drug is classified under ATC code C02AC01 for antihypertensives.

The United States FDA approved clonidine in 1974 and subsequently approved products such as Catapres and Kapvay for labeled indications.

The EMA permits registration for hypertension, ADHD, and pain management across member states, and Australia’s TGA classifies clonidine as Schedule 4 (prescription only) with some labeling listing pregnancy category B3.

Because many formulations are generic, prescribers must follow local substitution rules and consider branded ER or patch proprietary protections that can affect availability and cost.

For off‑label uses, clinicians should document rationale and obtain informed consent where appropriate, and report adverse events to national pharmacovigilance systems.

Consolidated FAQ

Can clonidine be used for ADHD?

Yes. Kapvay and other extended‑release formulations are FDA‑approved for ADHD, with pediatric dosing often starting at 0.1 mg at bedtime and titrated per response.

How should clonidine be stopped?

Taper slowly under clinician guidance to reduce the risk of rebound hypertension and adrenergic symptoms.

What if a dose is missed?

Take the missed dose as soon as remembered unless it is close to the next scheduled dose; do not double up doses.

Is clonidine safe in pregnancy?

Use is individualized and requires discussion with obstetrics; some jurisdictions list clonidine under pregnancy category B3, so risk‑benefit must be considered.

Patch versus tablet — which is better?

Transdermal patches improve adherence and provide steady delivery, but they can cause local skin reactions and are typically more expensive than tablets.

What are overdose signs?

Severe hypotension, bradycardia, and CNS/respiratory depression are key overdose signs and require emergency care; activated charcoal may be advised in early ingestion.

Visual Guide

Suggested Diagrams

Which visuals can help patients and clinicians understand clonidine quickly?

Infographic of mechanism of action showing alpha‑2 receptor inhibition of norepinephrine release and imidazoline receptor contribution is useful for clinician education.

Dosing flowcharts for hypertension titration (start 0.1 mg twice daily → increase 0.1 mg every 1–2 weeks up to ~2.4 mg/day), ADHD bedtime ER titration (start 0.1 mg qHS → up to 0.4 mg/day), and withdrawal protocols (0.1–0.2 mg q4–6h) help standardize practice.

Formulation gallery displaying tablet strengths, ER tabs, patch strengths, and injectable concentrations assists pharmacy dispensing and patient recognition.

Patch application checklist with site rotation, avoiding heat sources, and storage instructions supports proper transdermal use.

Storage & Transport

How should clonidine be stored and shipped?

Tablets should be stored at controlled room temperature between 15–30°C (59–86°F) and protected from moisture.

Patches should be stored flat and sealed and kept away from heat and direct sunlight to maintain delivery performance and adhesion.

Injectable Duraclon requires sterile handling and temperature control per vial labeling and hospital policies.

During shipping, maintain moderate temperatures and chain‑of‑custody for prescription goods.

Dispose of unused medicine according to local take‑back regulations; do not flush patches or tablets down the toilet.

Fold used patches before disposal because they may still contain active drug and pose a risk to children or pets.

Guidelines For Proper Use

Initiation & Titration Checklist

What steps should a clinician follow when starting clonidine?

Perform baseline assessment including blood pressure, heart rate, renal and hepatic function, medication review, pregnancy status, and fall‑risk evaluation.

Select formulation based on indication: oral immediate or ER for hypertension and ADHD, patch for adherence challenges, epidural injection for specialist cancer pain control.

Initiate at low doses and titrate slowly, with elderly patients starting lower (for example 0.05 mg twice daily) and longer intervals between increases.

Educate patients about sedation, orthostatic symptoms, and the importance of not stopping clonidine suddenly.

Monitoring & Discontinuation

What monitoring is essential during therapy?

Check blood pressure and heart rate at baseline and during dose adjustments until on a stable regimen.

Monitor for excessive sedation, dizziness, skin reactions with patches, and signs of depression or mood change.

Coordinate tapering with other antihypertensives to avoid rebound hypertension and safely withdraw therapy.

Document informed consent for off‑label uses and report adverse events as required.

Delivery Across United States

Consolidated Takeaways For Clinicians And Patients

What are the practical, evidence‑based points to keep in mind when considering clonidine?

Use extended‑release clonidine (Kapvay, Nexiclon XR) for ADHD when non‑stimulant therapy is preferred or when sleep onset is a major problem.

Consider transdermal Catapres‑TTS for elderly hypertensive patients with adherence barriers, recognizing higher patch cost and risk of local skin reactions.

Reserve epidural Duraclon for specialist management of severe cancer pain as an opioid‑sparing adjuvant under close monitoring.

Always start low and titrate slowly with frequent BP and HR monitoring, especially in elderly and renally impaired patients.

Educate patients clearly about sedation, orthostatic symptoms, and the need for gradual tapering to avoid rebound hypertension.

Concluding FAQ

Is clonidine appropriate for my condition?

Appropriateness depends on the indication, comorbidities, and risk profile; follow FDA‑approved labeling for hypertension and ADHD, and document rationale for off‑label uses.

How quickly will clonidine work?

Some effects on blood pressure and withdrawal symptoms can appear within hours to days, while behavioral benefits in ADHD with ER formulations may take several days to weeks depending on titration.

Who should I call in an emergency?

For signs of severe hypotension, bradycardia, or respiratory depression, seek emergency medical care immediately.

Where can I get more practical help?

Discuss dosing adjustments with your prescriber and request pharmacist counseling on patch application and storage when using transdermal products.